Century Therapeutics closed at $1.67 on Nov 4, up 9.87%, 43.2% below its 52-week closing high. Volume of 747.4K shares was 0.76× its 20-day average (below normal).
Split-adjusted performance: +26.5% over one month, -28.6% over six months, +178.3% over one year.
Short interest was 29.1M shares at the Oct 15 settlement (23.4% of float, 29.2 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IPSCCentury Therapeutics | $1.67 | +9.87% | −28.6% | — | — | — | $302.4M | |
| OCGNOcugen | $0.8745 | +17.35% | −39.9% | +8.4% | −1671.8% | — | $296.6M | Compare |
| AGENAgenus | $6.97 | +4.50% | +79.2% | +34.4% | −1.7% | 3.4 | $314.8M | Compare |
| SABSSAB Biotherapeutics | $3.18 | +1.92% | −16.3% | — | — | — | $289.3M | Compare |
| SCTXScribe Therapeutics | $16.78 | +3.58% | — | — | — | — | $317.7M | Compare |
| KYTXKyverna Therapeutics | $5.16 | 0.00% | −45.5% | — | — | — | $319.1M | Compare |
| XFORX4 Pharmaceuticals | $3.24 | +2.21% | −26.0% | +346.3% | −183.5% | — | $321.2M | Compare |
| LXEOLexeo Therapeutics | $3.23 | +3.86% | −48.2% | — | — | — | $265.1M | Compare |
| EIKNEikon Therapeutics | $6.39 | +15.14% | −35.9% | — | — | — | $346.1M | Compare |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
